Key result
The IRS-1Gly972Arg genetic variant did not increase the risk of PCOS in Kashmiri women (OR 0.87; 95% CI 0.59-1.29; p=0.499), but was associated with markers of insulin resistance and obesity.
Why the study?
Genetic variants regulating insulin action may influence PCOS development and severity, prompting investigation into whether the IRS-1Gly972Arg polymorphism is associated with PCOS risk and clinical manifestations in Kashmiri women.
Is the IRS-1Gly972Arg (rs1801278) polymorphism associated with increased risk of PCOS or its metabolic manifestations in Kashmiri women?
Case-Control
Is the IRS-1Gly972Arg (rs1801278) polymorphism associated with increased risk of PCOS or its metabolic manifestations in Kashmiri women?
Odds Ratio: 0.87 (95% CI 0.59–1.29)
p-value: p=0.499
The IRS-1Gly972Arg polymorphism does not increase PCOS risk in Kashmiri women but is associated with clinical manifestations of insulin resistance and obesity.
Does not support IRS-1Gly972Arg as PCOS risk factor; leaves open its links to obesity and insulin resistance in affected women.
Background: Polycystic ovary syndrome (PCOS) is commonly associated with metabolic abnormalities such as hyperinsulinemia, insulin resistance and obesity. The genetic variants of genes regulating insulin action, expression and regulation are suggested as possible factors involved in development and severity of clinical manifestations in PCOS. Aim: We investigated whether IRS-1Gly972Arg (rs1801278) polymorphism is associated with increased risk of PCOS in Kashmiri women. The correlation of various clinical, metabolic and hormonal markers with rs1801278 single nucleotide polymorphism was analyzed. The genotypic−phenotypic association of clinical manifestations of PCOS with the tested genetic variant was also assessed. Results: There were no significant differences in allele frequency (OR = 0.87, CI = 0.59−1.29, χ2 = 0.456, p = 0.499) or genotypic distribution (χ2 = 3.73, p = 0.15) between PCOS women and controls. No significant association was also found in the dominant (OR = 1.63, χ2 = 0.377, p = 0.53), recessive (OR = 0.79, χ2 = 1.01, p = 0.31) or heterozygote vs. homozygote (OR = 1.34, χ2 = 1.53, p = 0.22) genotype model analysis. The genotype−phenotype correlation analysis showed that the Arg allele was significantly associated with increased central adiposity markers hip circumference (p = 0.012), and body adiposity index BAI (p = 0.002) in the recessive model in PCOS women. The two-hour glucose (p = 0.04) and insulin resistance marker HOMA (p = 0.44) were significantly higher in Arg allele carriers. The androgen excess markers dehydroepiandrosterone sulfate DHEAS (p = 0.02), Ferriman−Gallwey score (p = 0.012), prevalence of acne, alopecia and hirsutism (all p < 0.01) were significantly elevated in the wild-type GG genotype. Conclusions:IRS-1Gly972Arg genetic variant does not increase the risk of PCOS in Kashmiri women. However, this polymorphism is associated with clinical manifestations of insulin resistance, obesity and hyperandrogenism, suggesting its possible role in variable phenotypic manifestations of PCOS.
No takes yet. Share an insight, caveat, or question.
Rasool et al. (2022) conducted a case-control in Polycystic ovary syndrome (PCOS). IRS-1Gly972Arg (rs1801278) polymorphism vs. Controls (without PCOS) was evaluated on Risk of PCOS (allele frequency) (OR 0.87, 95% CI 0.59-1.29, p=0.499). The IRS-1Gly972Arg genetic variant did not increase the risk of PCOS in Kashmiri women (OR 0.87; 95% CI 0.59-1.29; p=0.499), but was associated with markers of insulin resistance and obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: